Answers are grounded in this paper and cite their sources.
Mucin 16 ( MUC16 ), a transmembrane mucin carrying the antigenic epitopes detected clinically in serum as CA125, has been implicated in cancer progression, but its expression landscape, prognostic significance, and immunological associations remain incompletely characterized from a pan-cancer perspective. This study integrated transcriptomic, proteomic, single-cell transcriptomic, spatial transcriptomic, immune infiltration, and pharmacogenomic data to characterize MUC16 across cancer types, with clinical analyses using peripheral blood test data and tumor tissue immunohistochemistry staining. Pan-cancer analyses revealed cancer-type-specific MUC16 dysregulation and heterogeneous prognostic associations, while its mutations were most frequently observed in melanoma and NSCLC. Pathway analyses revealed associations between MUC16 expression and multiple oncogenic as well as immune-related pathways. Higher MUC16 expression was preferentially detected in malignant-cell populations, with inverse associations with several immune-cell populations, including CD8⁺ T cells. Correlation analyses identified TFAP2A , VTCN1 , and hsa-miR-21-5p as molecular factors associated with MUC16 expression. Clinical analyses further showed increased MUC16 protein expression in LUAD tissues and associations of serum CA125 levels with lower total lymphocyte and CD3⁺ T-cell counts. Computational drug analyses identified candidate compounds and pharmacogenomic associations for subsequent validation. Collectively, these findings support the prognostic and immunological relevance of MUC16 , warranting further experimental and clinical investigation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: